PL2155188T3 - Sposoby i kompozycje do leczenia nawrotowego raka - Google Patents
Sposoby i kompozycje do leczenia nawrotowego rakaInfo
- Publication number
- PL2155188T3 PL2155188T3 PL08768111T PL08768111T PL2155188T3 PL 2155188 T3 PL2155188 T3 PL 2155188T3 PL 08768111 T PL08768111 T PL 08768111T PL 08768111 T PL08768111 T PL 08768111T PL 2155188 T3 PL2155188 T3 PL 2155188T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- methods
- recurrent cancer
- treating recurrent
- treating
- Prior art date
Links
- 206010038111 Recurrent cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93275007P | 2007-06-01 | 2007-06-01 | |
| EP08768111.0A EP2155188B1 (en) | 2007-06-01 | 2008-06-02 | Methods and compositions for treating recurrent cancer |
| PCT/US2008/007024 WO2008150532A1 (en) | 2007-06-01 | 2008-06-02 | Methods and compositions for treating recurrent cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2155188T3 true PL2155188T3 (pl) | 2014-03-31 |
Family
ID=39733105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08768111T PL2155188T3 (pl) | 2007-06-01 | 2008-06-02 | Sposoby i kompozycje do leczenia nawrotowego raka |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8927019B2 (enExample) |
| EP (1) | EP2155188B1 (enExample) |
| JP (3) | JP5579057B2 (enExample) |
| AU (1) | AU2008260447B2 (enExample) |
| CA (1) | CA2689914C (enExample) |
| DK (1) | DK2155188T3 (enExample) |
| ES (1) | ES2435452T3 (enExample) |
| HR (1) | HRP20131142T1 (enExample) |
| PL (1) | PL2155188T3 (enExample) |
| PT (1) | PT2155188E (enExample) |
| WO (1) | WO2008150532A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| ES2678448T3 (es) | 2005-02-18 | 2018-08-10 | Abraxis Bioscience, Llc | Combinaciones y modos de administración de agentes terapéuticos y terapia combinada |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| TWI417114B (zh) | 2005-08-31 | 2013-12-01 | Abraxis Bioscience Llc | 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| KR20090118999A (ko) * | 2007-03-07 | 2009-11-18 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| EP3326630A3 (en) * | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| DK2155188T3 (da) | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| CA2721153C (en) * | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| NZ598801A (en) * | 2009-09-18 | 2014-07-25 | Abraxis Bioscience Llc | Use of the sparc microenvironment signature in the treatment of cancer |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| NZ628423A (en) | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
| AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| WO2011153485A2 (en) | 2010-06-03 | 2011-12-08 | Abraxis Bioscience, Llc | Use of the sparc microenvironment signature in the treatment of cancer |
| RU2576609C2 (ru) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| CA3063641A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| DK2790675T3 (da) | 2011-12-14 | 2019-09-09 | Abraxis Bioscience Llc | Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler |
| DK2846809T3 (da) * | 2012-05-09 | 2021-01-18 | Cantex Pharmaceuticals Inc | Behandling af myelosuppression |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| NZ630392A (en) | 2013-03-12 | 2016-10-28 | Abraxis Bioscience Llc | Methods of treating lung cancer |
| WO2017161387A1 (en) * | 2016-03-18 | 2017-09-21 | Reid Christopher Brian | Compositions of natural extracts and use thereof in methods for preventing or treating diseases |
| RU2015143490A (ru) | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| BR112017011536A2 (pt) | 2014-12-02 | 2018-02-27 | Celgene Corp | terapias de combinação |
| WO2016133910A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| HUE070408T2 (hu) | 2015-06-29 | 2025-06-28 | Abraxis Bioscience Llc | Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra |
| AU2016323770A1 (en) * | 2015-09-16 | 2018-03-29 | Dfb Soria, Llc | Delivery of drug nanoparticles and methods of use thereof |
| CN105412024B (zh) | 2015-12-14 | 2018-03-30 | 广州帝奇医药技术有限公司 | 靶向疏水性抗肿瘤药物纳米制剂及其制备方法 |
| EP3407869A1 (en) * | 2016-01-27 | 2018-12-05 | Instar Technologies A.S. | Oromucosal nanofiber carriers for therapeutic treatment |
| AU2017219901B2 (en) | 2016-02-19 | 2022-07-14 | Nant Holdings Ip, Llc | Methods of immunogenic modulation |
| CN110461311A (zh) * | 2016-08-26 | 2019-11-15 | 奥野哲治 | 微细纳米化药剂及其应用 |
| CN118948828A (zh) | 2017-03-15 | 2024-11-15 | Dfb索里亚有限责任公司 | 使用紫杉烷纳米颗粒治疗皮肤恶性肿瘤的局部疗法 |
| JP7372252B2 (ja) | 2018-03-16 | 2023-10-31 | ディーエフビー ソリア リミテッド ライアビリティ カンパニー | タキサンのナノ粒子を用いる子宮頸部上皮内腫瘍（ｃｉｎ）および子宮頸癌の処置のための局所療法 |
| WO2019183146A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| EP3801069A4 (en) | 2018-06-01 | 2022-03-16 | Cornell University | MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K |
| JP2022553426A (ja) | 2019-10-28 | 2022-12-22 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| WO2023070023A1 (en) * | 2021-10-21 | 2023-04-27 | Faeth Therapeutics, Inc. | Combination therapy for pik3ca-associated diseases or disorders |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| IT1197485B (it) * | 1986-10-07 | 1988-11-30 | Boehringer Biochemia Srl | Composizioni farmaceutiche ad attivita' antineoplastica |
| US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US5650156A (en) * | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5665383A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US20070117863A1 (en) | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6528067B1 (en) * | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6753006B1 (en) * | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| WO1994018954A1 (en) * | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
| US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| EP1683517A1 (en) | 1996-08-19 | 2006-07-26 | American Bioscience, Inc. | Methods for the production of protein particles useful for delivery of pharmacological agents |
| US8137684B2 (en) * | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| PL335891A1 (en) * | 1997-03-27 | 2000-05-22 | Baker Norton Pharma | Methods of and compositions for treating ovarian carcinoma |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| PT1023050E (pt) | 1997-06-27 | 2013-12-04 | Abraxis Bioscience Llc | Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| AU777528B2 (en) | 1999-04-22 | 2004-10-21 | Abraxis Bioscience, Llc | Long term administration of pharmacologically active agents |
| WO2000071079A2 (en) | 1999-05-21 | 2000-11-30 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| EP1385551B1 (en) | 2001-04-06 | 2008-09-03 | Wyeth | Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| CA2480809A1 (en) * | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| US20040126400A1 (en) * | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
| MXPA05006169A (es) | 2002-12-09 | 2006-03-30 | American Biosciences | Composiciones y metodos para el suministro de agentes farmacologicos. |
| EP1585548B1 (en) * | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| AU2003293529A1 (en) * | 2002-12-16 | 2004-07-29 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| US20050119330A1 (en) * | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| US20050038498A1 (en) * | 2003-04-17 | 2005-02-17 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
| US20050152979A1 (en) * | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
| DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| MXPA06013191A (es) | 2004-05-14 | 2007-07-24 | Abraxis Bioscience Inc | Metodos de tratamiento que utilizan proteinas que enlazan albumina como objetivos. |
| KR101341359B1 (ko) * | 2004-10-01 | 2013-12-13 | 램스코르 인코포레이티드 | 편리하게 이식가능한 서방형 약물 조성물 |
| WO2006053754A1 (en) | 2004-11-19 | 2006-05-26 | Novartis Ag | COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE |
| ES2678448T3 (es) | 2005-02-18 | 2018-08-10 | Abraxis Bioscience, Llc | Combinaciones y modos de administración de agentes terapéuticos y terapia combinada |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN101146514B (zh) | 2005-02-18 | 2013-03-27 | 阿布拉西斯生物科学公司 | 用于整合入医疗装置的疏水性改善的药物 |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| BRPI0606282A2 (pt) * | 2005-03-17 | 2009-06-09 | Elan Pharma Int Ltd | composições injetáveis de compostos imunossupressores em nanopartìculas |
| US7514549B2 (en) * | 2005-04-16 | 2009-04-07 | Michigan State University | Tumor inhibition by modulating sprouty expression or activity |
| US20080214595A1 (en) | 2005-05-16 | 2008-09-04 | Seigo Izumo | Use Of Rapamycin Derivatives For The Treatment And/Or Prevention Of Cardiovas Cular Disorders |
| JP5368093B2 (ja) | 2005-08-31 | 2013-12-18 | アブラクシス バイオサイエンス， エルエルシー | 増大した安定性を有する難水溶性薬剤の組成物および調製の方法 |
| TWI417114B (zh) | 2005-08-31 | 2013-12-01 | Abraxis Bioscience Llc | 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 |
| CA2662140A1 (en) | 2006-08-31 | 2008-03-06 | Abraxis Bioscience, Llc | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| ITFI20060277A1 (it) * | 2006-11-08 | 2008-05-09 | Giuliano Giustini | Sollevatore per motociclette e simili, offrente mobilita' di spostamenti omnidirezionali |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| KR20090118999A (ko) | 2007-03-07 | 2009-11-18 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| EP3326630A3 (en) | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| DK2155188T3 (da) | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| CA2721153C (en) * | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| BRPI0922823A2 (pt) * | 2008-12-11 | 2015-08-18 | Abraxis Bioscience Llc | Combinações e modos de administração de agentes terapêuticos e terapia de combinação |
| AU2010224012B2 (en) * | 2009-03-13 | 2016-04-28 | Abraxis Bioscience, Llc | Combination therapy with thiocolchicine derivatives |
| CA2758200A1 (en) * | 2009-04-10 | 2010-10-14 | Abraxis Bioscience, Llc | Nanoparticle formulations and uses thereof |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| NZ598588A (en) * | 2009-08-25 | 2014-05-30 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| US9775819B2 (en) * | 2009-09-16 | 2017-10-03 | R.P. Scherer Technologies, Llc | Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin |
| US8269348B2 (en) * | 2010-02-22 | 2012-09-18 | Texas Instruments Incorporated | IC die including RDL capture pads with notch having bonding connectors or its UBM pad over the notch |
| ES2580135T3 (es) * | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| AU2011232862B2 (en) * | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| NZ628423A (en) * | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
| MY188911A (en) | 2010-06-02 | 2022-01-13 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| RU2576609C2 (ru) * | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| KR101850566B1 (ko) * | 2010-06-07 | 2018-04-19 | 아브락시스 바이오사이언스, 엘엘씨 | 증식성 질환의 치료를 위한 조합 치료 방법 |
| US8871256B2 (en) * | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
| US9149455B2 (en) * | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) * | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199404A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
-
2008
- 2008-06-02 DK DK08768111.0T patent/DK2155188T3/da active
- 2008-06-02 JP JP2010510376A patent/JP5579057B2/ja active Active
- 2008-06-02 WO PCT/US2008/007024 patent/WO2008150532A1/en not_active Ceased
- 2008-06-02 ES ES08768111T patent/ES2435452T3/es active Active
- 2008-06-02 PL PL08768111T patent/PL2155188T3/pl unknown
- 2008-06-02 HR HRP20131142AT patent/HRP20131142T1/hr unknown
- 2008-06-02 AU AU2008260447A patent/AU2008260447B2/en active Active
- 2008-06-02 EP EP08768111.0A patent/EP2155188B1/en active Active
- 2008-06-02 US US12/600,991 patent/US8927019B2/en active Active
- 2008-06-02 CA CA2689914A patent/CA2689914C/en active Active
- 2008-06-02 PT PT87681110T patent/PT2155188E/pt unknown
-
2013
- 2013-02-28 US US13/781,482 patent/US20140017316A1/en not_active Abandoned
-
2014
- 2014-07-08 JP JP2014140474A patent/JP2014185186A/ja active Pending
- 2014-11-21 US US14/550,509 patent/US20160158365A9/en not_active Abandoned
-
2016
- 2016-07-07 JP JP2016134757A patent/JP2016172777A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5579057B2 (ja) | 2014-08-27 |
| US20150079181A1 (en) | 2015-03-19 |
| US20100215751A1 (en) | 2010-08-26 |
| HRP20131142T1 (hr) | 2014-01-03 |
| US8927019B2 (en) | 2015-01-06 |
| EP2155188A1 (en) | 2010-02-24 |
| JP2010529025A (ja) | 2010-08-26 |
| JP2014185186A (ja) | 2014-10-02 |
| HK1140944A1 (en) | 2010-10-29 |
| ES2435452T3 (es) | 2013-12-19 |
| CA2689914C (en) | 2016-08-16 |
| DK2155188T3 (da) | 2013-11-04 |
| WO2008150532A1 (en) | 2008-12-11 |
| US20140017316A1 (en) | 2014-01-16 |
| US20160158365A9 (en) | 2016-06-09 |
| PT2155188E (pt) | 2013-12-19 |
| AU2008260447A1 (en) | 2008-12-11 |
| JP2016172777A (ja) | 2016-09-29 |
| CA2689914A1 (en) | 2008-12-11 |
| EP2155188B1 (en) | 2013-10-09 |
| AU2008260447B2 (en) | 2013-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2155188T3 (pl) | Sposoby i kompozycje do leczenia nawrotowego raka | |
| IL257681A (en) | Methods and compositions for the treatment of cancer | |
| SI2173379T1 (sl) | Sestavki in postopki za zdravljenje in diagnosticiranje raka | |
| PT2200431T (pt) | Novos métodos e composições para o tratamento do cancro | |
| ZA200901615B (en) | Compositions and methods for diagnosing and treating cancer | |
| PL2032166T3 (pl) | Kompozycje i sposoby diagnozowania i leczenia nowotworów | |
| IL218987A0 (en) | Methods and compositions for treating cancer | |
| PL2340042T3 (pl) | Sposoby i kompozycje do leczenia raka | |
| EP2211854A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS | |
| EP2231185A4 (en) | METHOD AND COMPOSITIONS FOR TREATING LIQUID TUMORS | |
| EP2049151A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| ZA200708575B (en) | Methods and compositions for treating or preventing cancer | |
| PL2481756T3 (pl) | Kompozycje i sposoby diagnozowania i leczenia nowotworu | |
| IL210097A0 (en) | Compositions and methods for treating unfluenza | |
| HRP20130642T1 (en) | Methods and compositions for treating cancers | |
| EP2176406A4 (en) | COMPOSITIONS AND METHOD FOR CANCER TREATMENT | |
| IL204945A0 (en) | Compositions and methods for inhibiting tumor progression | |
| EP2144888A4 (en) | METHODS OF TREATING CANCER | |
| EP2137213A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER | |
| IL199911A0 (en) | 3-cinnolinecarboxamide derivatives and their use for treating cancer | |
| EP1855662A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
| ZA200808600B (en) | Methods and compositions for the detection and treatment of cancers | |
| GB0822345D0 (en) | Methods and compositions for cancer prognosis | |
| SI3067054T1 (sl) | Novi sestavki in postopki za zdravljenje raka | |
| PT3067054T (pt) | Novas composições e métodos para o tratamento de cancro |